The Manufacturers Life Insurance Company Makes New $534,000 Investment in Alto Neuroscience, Inc. $ANRO

The Manufacturers Life Insurance Company acquired a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 23,747 shares of the company’s stock, valued at approximately $534,000.

Several other large investors also recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the 1st quarter worth about $52,000. Torren Management LLC acquired a new position in Alto Neuroscience in the 4th quarter valued at about $62,000. Invesco Ltd. acquired a new position in Alto Neuroscience in the 1st quarter valued at about $67,000. Bridgeway Capital Management LLC raised its holdings in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in Alto Neuroscience in the 4th quarter valued at about $198,000.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $32.14 on Friday. The firm has a 50-day moving average price of $25.97 and a two-hundred day moving average price of $22.75. Alto Neuroscience, Inc. has a 12-month low of $3.05 and a 12-month high of $33.67. The company has a market capitalization of $1.13 billion, a P/E ratio of -13.28 and a beta of 1.06. The company has a quick ratio of 20.52, a current ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. Analysts anticipate that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analyst Weigh In

ANRO has been the subject of several research reports. BTIG Research raised their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday. Wolfe Research assumed coverage on Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. Robert W. Baird lowered their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Zacks Research lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Finally, Wall Street Zen upgraded Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.62.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.